Incredible World First Ribcage Implant Becomes ‘alive’
MELBOURNE, Australia, Nov. 16, 2021 /PRNewswire/ -- Innovative medical device manufacturer Anatomics Pty Ltd announces the world first use of revolutionary StarPore polymer tissue scaffold for thoracic reconstructive surgery in Australia, USA, UK, Singapore, Portugal and New Zealand. To view the Multimedia News Release, please click: https://www.prnasia.com/mnr/Anatomics-Incredible-World-First-Ribcage-Implant-Becomes-alive.shtml Massive ribcage reconstruction planned with AnatomicsRx C3D software. StarPore ribcage...
Infinitus Celebrates Grand Opening of Guangzhou Infinitus Plaza
GUANGZHOU, China, Nov. 16, 2021 /PRNewswire/ -- On the morning of 9 November 2021, Infinitus grandly hosted its Opening Ceremony of the Guangzhou Infinitus Plaza! After 5 years of construction, with a total investment of RMB 4.5 billion, the 185,470-square meter plaza is finally complete. This represents the headquarters of Infinitus Global, the Global Research Centre and the...
EDAN Revealed Its Blueprint on Speeding Up Clinic Workflow at MEDICA 2021
DUSSELDORF, Germany, Nov. 16, 2021 /PRNewswire/ -- EDAN Instruments, Inc. (300206.SZ), a leading healthcare company in the field of Obstetrics and Gynecology, Diagnostic ECG, Patient Monitoring, Ultrasound Imaging, and In-Vitro Diagnostics, re-emphasis its value proposition at MEDICA 2021 with its next-gen products. Five new products are presented to give a preview of EDAN's effort on the improvement of...
Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer
SYDNEY, Nov. 16, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the appointment of John Friend, MD, as Chief Medical Officer. In this role, Dr. Friend will be responsible for overseeing the development and commercialization of Kazia's pipeline drug candidates,...
Lunit Gets FDA Nod for AI-based Chest X-ray Triage Solution, Developed for Sorting of Emergency Cases
- First FDA 510(k) clearance from its AI software product lineup for radiology, specialized in triaging emergent cases found in chest x-ray - Company to accelerate business in the US market, leveraging partnerships with Philips, FujiFilm - Product to be introduced during RSNA 2021 booth #4545 SEOUL, South Korea, Nov. 15,...
Nanoform signs GMP agreement and achieves near-term business target
HELSINKI, Nov. 15, 2021 /PRNewswire/ -- Insider information Nanoform Finland Plc November 15, 2021 05:05 p.m. Finnish time / 04:05 p.m. Swedish time Nanoform signs GMP agreement and achieves near-term business target Helsinki, Finland - Nanoform, an innovative nanoparticle medicine enabling company, today announced it has signed an agreement to manufacture GMP (Good Manufacturing Practice) nanoformed material for...
R&D Milestone: HebaBiz Biotech’s application for phase III clinical trial in China for Clevudine (L-FMAU), an anti-hepatitis B virus drug candidate under development has been approved
BEIJING, Nov. 15, 2021 /PRNewswire/ -- HebaBiz Biotech is pleased to announce that in November 2021, the Center for Drug Evaluation (CDE) of The National Medical Products Administration (NMPA) of China has approved the application for phase III clinical study of Clevudine (L-FMAU), a drug candidate under development for chronic hepatitis B virus (HBV), the application of which was...
Novavax Announces Submission of Biologics License Application in South Korea for Approval of NVX-CoV2373
GAITHERSBURG, Md., Nov. 15, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited (SK bioscience), a biotechnology company in South Korea, today announced the submission of a Biologics License Application (BLA) for Novavax' COVID-19 vaccine to...
CARsgen Announces CAR T-cell Product Candidate CT041 Granted PRIME Eligibility by the EMA
SHANGHAI, Nov. 15, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) eligibility to CT041, an autologous CAR T-cell product candidate against the claudin18.2 protein (CLDN18.2) for the...
RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients
- Recruitment completed for Part A of the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care - Top-line results for Part A of the study, designed to evaluate safety and tolerability of RHB-107 and dose selection, expected in Q1/ 22 - RHB-107 is...
